INTRODUCTION: Although warfarin has traditionally been used for reducing risk of stroke in patients with atrial fibrillation, over the past year, the direct thrombin inhibitor dabigatran has become an accepted alternative. No study has conclusively investigated bleeding risks of patients treated with dabigatran immediately following radiofrequency catheter ablation (RFCA) procedures. METHODS: We evaluated 156 consecutive patients referred for RFCA of atrial arrhythmias: 31 patients were on dabigatran and 125 patients were on warfarin. The incidence of bleeding complications during the first 48 h and the first week following ablation were recorded and comparisons made using Fisher's exact test. Major complications were defined as hemorrhage requiring blood products or the need for vascular intervention. Minor complications were defined as prolonged bleeding from the catheter insertion site, hematoma formation, or development of ecchymosis. Our study also took into account the intraprocedure activated clotting time (ACT) levels in an effort to describe any differences between both patient groups. RESULTS: There were no differences in age, gender, procedure type, or level of intraprocedural anticoagulation between the warfarin and dabigatran groups. No major bleeding complications were observed in either patient group at either 48 h or 1 week postprocedure. Six of the 31 dabigatran patients and 21 of the 125 warfarin patients had minor bleeding complications. There was no statistically significant difference between the incidence of minor bleeding complications between the two groups (p = 0.7384), although rebleeding was more commonly observed in patients on dabigatran. In regard to the intraprocedure ACT levels, there was more variability in the dabigatran patient group, and it was more difficult to achieve the goal ACT level, yet these results did not affect overall bleeding complications. CONCLUSION: In our cohort, bleeding-related complications 48 h and 1 week post-ablation were similar for warfarin and dabigatran. Dabigatran is associated with more intraprocedural variability in ACT than warfarin.
INTRODUCTION: Although warfarin has traditionally been used for reducing risk of stroke in patients with atrial fibrillation, over the past year, the direct thrombin inhibitor dabigatran has become an accepted alternative. No study has conclusively investigated bleeding risks of patients treated with dabigatran immediately following radiofrequency catheter ablation (RFCA) procedures. METHODS: We evaluated 156 consecutive patients referred for RFCA of atrial arrhythmias: 31 patients were on dabigatran and 125 patients were on warfarin. The incidence of bleeding complications during the first 48 h and the first week following ablation were recorded and comparisons made using Fisher's exact test. Major complications were defined as hemorrhage requiring blood products or the need for vascular intervention. Minor complications were defined as prolonged bleeding from the catheter insertion site, hematoma formation, or development of ecchymosis. Our study also took into account the intraprocedure activated clotting time (ACT) levels in an effort to describe any differences between both patient groups. RESULTS: There were no differences in age, gender, procedure type, or level of intraprocedural anticoagulation between the warfarin and dabigatran groups. No major bleeding complications were observed in either patient group at either 48 h or 1 week postprocedure. Six of the 31 dabigatranpatients and 21 of the 125 warfarinpatients had minor bleeding complications. There was no statistically significant difference between the incidence of minor bleeding complications between the two groups (p = 0.7384), although rebleeding was more commonly observed in patients on dabigatran. In regard to the intraprocedure ACT levels, there was more variability in the dabigatranpatient group, and it was more difficult to achieve the goal ACT level, yet these results did not affect overall bleeding complications. CONCLUSION: In our cohort, bleeding-related complications 48 h and 1 week post-ablation were similar for warfarin and dabigatran. Dabigatran is associated with more intraprocedural variability in ACT than warfarin.
Authors: Dhanunjaya Lakkireddy; Yeruva Madhu Reddy; Luigi Di Biase; Subba Reddy Vanga; Pasquale Santangeli; Vijay Swarup; Rhea Pimentel; Moussa C Mansour; Andre D'Avila; Javier E Sanchez; J David Burkhardt; Fadi Chalhoub; Prasant Mohanty; James Coffey; Naushad Shaik; George Monir; Vivek Y Reddy; Jeremy Ruskin; Andrea Natale Journal: J Am Coll Cardiol Date: 2012-02-01 Impact factor: 24.094
Authors: L Samuel Wann; Anne B Curtis; Kenneth A Ellenbogen; N A Mark Estes; Michael D Ezekowitz; Warren M Jackman; Craig T January; James E Lowe; Richard L Page; David J Slotwiner; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; G Neal Kay; Jean-Yves Le Heuzey; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; L Samuel Wann; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Mark A Creager; Steven M Ettinger; Robert A Guyton; Jonathan L Halperin; Judith S Hochman; Frederick G Kushner; Erik Magnus Ohman; William G Stevenson; Clyde W Yancy Journal: Circulation Date: 2011-02-14 Impact factor: 29.690
Authors: Prabashni Reddy; Julie K Atay; Leslie G Selbovitz; Jean Marie Connors; Gregory Piazza; Caroline Cole Block; Paul A Arpino; Nancy Berliner; Adolph M Hutter; Michael A Fischer; David Kuter; James Weitzman; Geoffery K Sherwood; Avraham Almozlino; Robert P Giugliano Journal: Crit Pathw Cardiol Date: 2011-09
Authors: John W Eikelboom; Lars Wallentin; Stuart J Connolly; Mike Ezekowitz; Jeff S Healey; Jonas Oldgren; Sean Yang; Marco Alings; Scott Kaatz; Stefan H Hohnloser; Hans-Christoph Diener; Maria Grazia Franzosi; Kurt Huber; Paul Reilly; Jeanne Varrone; Salim Yusuf Journal: Circulation Date: 2011-05-16 Impact factor: 29.690
Authors: Rangadham Nagarakanti; Michael D Ezekowitz; Jonas Oldgren; Sean Yang; Michael Chernick; Timothy H Aikens; Greg Flaker; Josep Brugada; Gabriel Kamensky; Amit Parekh; Paul A Reilly; Salim Yusuf; Stuart J Connolly Journal: Circulation Date: 2011-01-03 Impact factor: 29.690
Authors: Stefan H Hohnloser; Jonas Oldgren; Sean Yang; Lars Wallentin; Michael Ezekowitz; Paul Reilly; John Eikelboom; Martina Brueckmann; Salim Yusuf; Stuart J Connolly Journal: Circulation Date: 2012-01-03 Impact factor: 29.690
Authors: Lars Wallentin; Salim Yusuf; Michael D Ezekowitz; Marco Alings; Marcus Flather; Maria Grazia Franzosi; Prem Pais; Antonio Dans; John Eikelboom; Jonas Oldgren; Janice Pogue; Paul A Reilly; Sean Yang; Stuart J Connolly Journal: Lancet Date: 2010-09-18 Impact factor: 79.321
Authors: Benjamin A Steinberg; Vic Hasselblad; Brett D Atwater; Tristram D Bahnson; Jeffrey B Washam; John H Alexander; James P Daubert; Jonathan P Piccini Journal: J Interv Card Electrophysiol Date: 2013-07-24 Impact factor: 1.900
Authors: L C Brendel; F Dobler; G Hessling; J Michel; S L Braun; A L Steinsiek; P Groha; R Eckl; I Deisenhofer; A Hyseni; M Roest; I Ott; B Steppich Journal: J Interv Card Electrophysiol Date: 2017-07-22 Impact factor: 1.900
Authors: Aysha Arshad; Christopher K Johnson; Suneet Mittal; Eric Buch; Ismail Hamam; Thanh Tran; Richard E Shaw; Dan Musat; Mark Preminger; Tina Sichrovsky; Bengt Herweg; Kalyanam Shivkumar; John Hummel; Jonathan S Steinberg Journal: Pacing Clin Electrophysiol Date: 2014-05-04 Impact factor: 1.976
Authors: David Snipelisky; Jordan C Ray; Ryan Ung; Melissa Duart; Christine Kauffman; Fred Kusumoto Journal: J Interv Card Electrophysiol Date: 2014-11-08 Impact factor: 1.900